Loading...
Mycobacterium abscessus is a rapid-growing nontuberculous mycobacterium (NTM) that can cause pulmonary infection in patients with structural lung disease and soft-tissue infection. It can be exceptionally challenging to treat because of intrinsic resistance to multiple antibiotic classes, including macrolides (cornerstones to NTM therapy). Tigecycline demonstrates good activity in vitro and in practice but often has excessive gastrointestinal side effects and is intravenous only. Last year, omadacycline, a novel aminomethylcycline, was FDA approved (in both intravenous and oral formulations) for the treatment of skin infection and pneumonia.
Driven by structural similarities between omadacycline and tigecycline, investigators compared the ac…